Guardant Health Announces Preliminary Fourth Quarter and Full Year 2025 Results
Fourth quarter revenue growth of 39% driven by strong Oncology and Screening volume PALO ALTO, Calif.–(BUSINESS WIRE)–Guardant Health, Inc. (Nasdaq:... Read more.
Tempus Announces Preliminary Fourth Quarter and Full Year 2025 Results
CHICAGO–(BUSINESS WIRE)–Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced... Read more.
Veracyte Announces Preliminary Fourth Quarter and Full-Year 2025 Results
Grew full-year revenue to between $515 million and $517 million, an increase of 16% SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Veracyte, Inc. (Nasdaq:... Read more.
Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026
– Cabozantinib franchise achieves approximately $2.123 billion in preliminary U.S. net product revenues for fiscal year 2025 – – Fiscal year 2026 net product... Read more.
Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2025 Product Revenue and Provides Outlook
Preliminary Full-Year 2025 Product Revenue of $206.1 Million Full-Year 2026 Product Revenue Expected to be $224 Million to $228 Million, Reflecting 9%-11% Growth,... Read more.
Vibe Retail POS Sets the Standard for Retail-Focused Point-of-Sale Technology
BROOKLYN, N.Y.–(BUSINESS WIRE)–#CloudPOS–As point-of-sale platforms increasingly expand to support restaurants, services, and multiple verticals,... Read more.
Direct Source Highlights the Hottest Retail Technology Innovations at NRF Big Show 2026
AI-driven checkout, RFID-powered experiences, sustainable business systems and enhanced in-store engagement tools will drive the in-store experience MINNEAPOLIS... Read more.
Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome
— Company now expects to complete enrollment of 150 patients in Q2 2026, with a Phase 3 data readout in mid-2027; Rolling NDA submission planned to initiate in... Read more.
Debiopharm Deploys Genialis Software to Advance AI-Based Biomarker Discovery
Genialis Expressions empowers drug development teams to make confident decisions by unifying workflows and standardizing omics data for enterprise-grade clarity... Read more.
Torq Secures $140M Series D at $1.2B Valuation to Lead the AI SOC and Agentic AI Era
Fueled by Massive Customer Adoption of AI Agents, Torq Scales the World’s First True AI SOC Platform and Accelerates Expansion into the U.S. Federal Market NEW... Read more.